

630 Route 303 Blauvelt, NY 10913

Tel: 845.727.4100 Fax: 845.727.4110

E-mail: shyla@cantorlabs.com

# 50 HUMAN SUBJECT REPEAT INSULT PATCH TEST SKIN IRRITATION/SENSITIZATION EVALUATION (OCCLUSIVE PATCH)

Date:

December 29, 2009

CR Ref. No.:

RIPT.G0917-A2.O.50.SENS.DERM.AMO.REV

Sponsor:

Amedico Corp

17W 173 16th Street

Oakbrook Terrace, Illinois 60181

## 1.0 Objective:

Consumer products or raw materials designed for consistent reapplication to areas of the skin may, under proper conditions, prove to be contact sensitizers or irritants in certain individuals. It is the intention of a Repeat Insult Patch Test (RIPT) to provide a basis for evaluation of this irritation/sensitization potential if such exists.

### 2.0 Reference:

The method is modified to test 50 panelists and not the 200 cited in the reference <u>Appraisal of the Safety of Chemicals in Food, Drugs and Cosmetics</u>, published by The Association of Food and Drug Officials of The United States. The method also employs nine inductive patchings and not the ten cited in the reference under occlusive patch conditions.

#### 3.0 Test Material:

## 3.1 Test Material Description:

On September 17, 2009, one test sample labeled MayLan Moisturizing Daily Cream, 9G11 was received from Amedico Corp and assigned CR Lab No. G0917-A2.

## 3.2 Test Material Handling:

Upon arrival at Cantor Research Laboratories, Inc., the test material was assigned a unique laboratory code number and entered into a daily log identifying the lot number, sample description, sponsor, date received and test(s) requested.

Samples are retained for a minimum period of three months beyond submission of final report unless otherwise specified by the sponsor. If the sample is known to be in support of governmental applications, samples are kept a minimum of two years beyond final report submission. Sample disposal is conducted in compliance with appropriate federal, state and local ordinances.

## 12.0 Conclusions:

The test material (CR Lab No.: G0917-A2; Client No.: MayLan Moisturizing Daily Cream, 9G11) when tested under occlusive conditions on a panel consisting of fifty seven subjects, with thirty four subjects self-described as having sensitive skin, may be considered as a <u>NON-PRIMARY IRRITANT</u> and a <u>NON-PRIMARY SENSITIZER</u> to the skin according to the reference.

Shyla	Cantor, Ph.D.
Study	Director

Mellodene Charles, A.A.S. Cert. EMT

Laboratory Manager

Michelle Peters, B.A. / Quality Assurance Supervisor

Animesh A. Sinha, M.D., Ph.D.

Dermatologist

Natacha Pierre, B.S.

Technician

Date